Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues
Total Revenue	$ 29,625,181	$ 40,519,800
Operating expenses
General and administrative	11,742,540	12,197,111
Research and development	9,240,020	9,079,351
Sales and marketing	4,686,932	611,571
Royalty expenses	6,196,706	7,720,280
Total operating expenses	31,866,198	29,608,313
Income (loss) from operations	(2,241,017)	10,911,487
Other income (expense)
Interest income, net	93,877	437,653
Interest expense	(131,007)	0
Gain on debt settlement	0	16,503
Gain (loss) on foreign exchange	(8,981)	50,172
Total other income (expense)	(46,111)	504,328
Income (loss) before income taxes	(2,287,128)	11,415,815
Income tax benefit	425,679	177,235
Net income (loss)	(1,861,449)	11,593,050
Other comprehensive income (loss)
Foreign Currency Translation Adjustments	(26,931)	0
Total comprehensive income (loss)	$ (1,888,380)	$ 11,593,050
Income (loss) per share of common stock:
Basic (in dollars per share)	$ (0.44)	$ 2.88
Diluted (in dollars per share)	$ (0.44)	$ 2.17
Weighted average common stock outstanding
Basic (in shares)	4,249,832	4,018,464
Diluted (in shares)	4,249,832	5,342,378
Royalty and licensing revenue
Revenues
Total Revenue	$ 27,401,919	$ 37,592,401
Treatment investment revenue
Revenues
Total Revenue	0	643,955
Grant and contract revenue
Revenues
Total Revenue	$ 2,223,262	$ 2,283,444